Medicine and biology: main business and profit increased by nearly 15% in the first half of the year

2013-09-02 source: as of August 30, the first financial daily reported an overall increase of 37.91% in the first half of Shenwan pharmaceutical and biological industry, ranking fourth among the 23 Shenwan level industries in terms of information services, information equipment and electronics Surpassing the performance of all a shares and small and medium-sized boards in the first half of the year, slightly inferior to the growth rate of 42.9% of the overall gem However, compared with the stock price performance of its "top students", the mid-year report card of the pharmaceutical and biological industry is only in the middle of the year: according to the data, the total operating revenue (total) of the pharmaceutical and biological companies in the first half of the year increased by 14.84% compared with the same period of last year, ranking No 6 next to real estate, electronics, building materials, information services and household appliances ; the total net profit attributable to the shareholders of the parent company increased by 14.56% year-on-year, ranking 11th in growth rate From the perspective of individual shares, the net profit of 12 companies increased by more than 100% year-on-year in the first half of the year; the growth rate of 26 companies exceeded 50%; and the growth rate of 44 companies was negative In addition, the net profit growth of Lingrui Pharmaceutical (600285 SH), Duyiwei Pharmaceutical (002219 SZ) and Kangzhi Pharmaceutical (300086 SZ) exceeded 200% In June, the company changed its name from Dongsheng Technology to guangyuyuan Among the hot stocks, the growth rate of Dean diagnostics (300244 SZ) and tag Pharmaceutical (300347 SZ) was also above 40% It is worth mentioning that Hejia shares (300273 SZ) rose 179% in the first half of the year, ranking fourth in the industry However, the year-on-year growth rate of operating revenue of Zhongbao was only 17.23%, and the year-on-year growth rate of net profit after deducting non recurring profit and loss was only 14.52% The company explained that in the first half of the year, the growth of sales revenue of main business slowed down compared with the same period of last year, mainly because the company currently has a large number of orders in hand, some projects are still in implementation, and the revenue recognition conditions are not met yet According to a notice released on August 19, the cooperation framework agreement signed by the company and Jingxian people's Government of Hebei Province in February this year with a total amount of no more than 102 million yuan will be terminated In the first half of the year, many pharmaceutical companies fell into losses Among them, Sihuan Pharmaceutical (000605 SZ) and Sihuan biological (000518 SZ) lost 2.065 million yuan and 1.181 million yuan respectively, with a large decline in net profit